Primary Mitochondrial Myopathy Clinical Trial
Official title:
An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment
The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03323749 -
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
|
Phase 3 | |
| Completed |
NCT04535609 -
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04641962 -
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
|
Phase 2/Phase 3 | |
| Terminated |
NCT05267574 -
An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)
|
Phase 2/Phase 3 |